FAP and pancreatic neoplasm: In an orthotopic, syngeneic mouse model of pancreatic cancer, FAP-IL-2v exhibited synergistic effects when combined with a murine anti-PD-L1 antibody, significantly improving the survival of mice compared to monotherapy with the anti-PD-L1 antibody (13).